Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Priority review designations

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

AstraZeneca's NDA for Entocort budesonide modified-release capsules is granted priority review. The application was submitted Jan. 24 for treatment of active, mild to moderate Crohn's disease. Three biologics also were recently given priority review status: Lilly's Zovant (drotrecogin alfa) for treatment of sepsis with associated acute organ dysfunction, submitted in late January; Novartis' Glivec (imatinab), submitted Feb. 27 for use in treatment of chronic myeloid leukemia in the blast crisis, accelerated or chronic phases of the disease after failure of interferon alpha; and Schering-Plough's sBLA for combination use of PEG-Intron (peginterferon alfa-2b) with Rebetrol (ribivarin) for treatment of chronic hepatitis C in adults who were not previously treated with interferon alpha who have compensated liver diseas

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS001445

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel